Copy Link Print Information

Nirogacestat dihydrobromide

(Synonyms: PF-3084014 dihydrobromide; PF-03084014 dihydrobromide)
15 Cited Publications
Customer Review

Based on 15 publication(s) in Google Scholar

Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers.

For research use only. We do not sell to patients.

  • Purity: 99.81%
  • CAS No.: 1962925-29-6
  • Formula: C27H43Br2F2N5O
  • Molecular Weight:651.47
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Nirogacestat dihydrobromide Chemical Structure
    Nirogacestat dihydrobromide Chemical Structure
  • Experimental Validation Results for Nirogacestat dihydrobromide
  • Experimental Validation Results for Nirogacestat dihydrobromide
  • Experimental Validation Results for Nirogacestat dihydrobromide
  • Experimental Validation Results for Nirogacestat dihydrobromide
  • Experimental Validation Results for Nirogacestat dihydrobromide
  • Experimental Validation Results for Nirogacestat dihydrobromide
CAS No.: 1962925-29-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Nirogacestat dihydrobromide:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Nirogacestat dihydrobromide

More
Customer Validation & Images
ELISAWBCell Proliferation/Viability Assay
  • ELISA
  • WB
  • ELISA
  • Cell Proliferation/Viability Assay
  • WB
  • WB
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Nirogacestat dihydrobromide Chemical Structure
    Nirogacestat dihydrobromide Chemical Structure
    1/16
  • 1/16

    Nirogacestat dihydrobromide purchased from MedChemExpress. Usage Cited in: Nat Med. 2023 Sep;29(9):2295-2306. [Abstract]

    Customer Validation
     Soluble BCMA was measured from the supernatant of K562 cell line cultures using the sBCMA DuoSet kit. The cell lines were cultured with the γ-secretase inhibitor Nirogacestat (PF-3084014) (6.2 nM).

  • 1/16

    Nirogacestat dihydrobromide purchased from MedChemExpress. Usage Cited in: Neuron. 2023 Jun 21;111(12):1898-1913.e5. [Abstract]

    Customer Validation
     Treatment with γ-secretase inhibitor Nirogacestat (PF03084014) (1 mM) increased α-CTF to a level similar to ApoE CT treatment in HEK 293T cells.

  • 1/16

    Nirogacestat dihydrobromide purchased from MedChemExpress. Usage Cited in: Neuron. 2023 Jun 21;111(12):1898-1913.e5. [Abstract]

    Customer Validation
     Aβ40 production was measured from the incubation of purified β-CTF (0.1 mM) alone or co-incubation with γ-secretase (0.001 mM) after treatment with vehicle or Nirogacestat (PF03084014) (10 mM).

  • 1/16

    Nirogacestat dihydrobromide purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2021 Mar 8;39(3):380-393.e8. [Abstract]

    Customer Validation
     Exposure to the gamma-secretase inhibitor Nirogacestat (PF308414) (6.2 nM), which targeted NOTCH signaling, led to decreased viability of mut-Ikzf3 CLL cells.

  • 1/16

    Nirogacestat dihydrobromide purchased from MedChemExpress. Usage Cited in: Int J Oncol. 2018 Jul;53(1):99-112. [Abstract]

    Customer Validation
     The expression of E-cadherin, N-cadherin and Snail in Enza-R cells is examined by western blot analysis. The cells are transfected with Ad-GFP or Ad-HepaCAM for 72 h and treated with 5 μM PF-3084014 for 48 h. GAPDH served as a loading control.

  • 1/16

    Nirogacestat dihydrobromide purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2017 Jul;9(7):950-966. [Abstract]

    Customer Validation
     Turnover of endogenous CD74 P8 is inhibited by RO4929079 and BMS-906024. Cell lysate Western blot of A20 cells treated with GSIs is developed with In-1 antibody. MK-0752 and Semagacestat tests used the same control lane (0 nM).

  • Nirogacestat dihydrobromide